Mr Jason Low has been appointed as Associate Product Manager (Pharmaceutical) for Singapore with effect from 11 October 2021.

Jason brings with him over 6 years of clinical and pharmaceutical experience from the healthcare and pharmaceutical industry, working across organizations such as MSD, Abbott and National Healthcare Group. As a licensed Pharmacist with business acumen, he has played a pivotal role in the launch of multiple brands under the vaccine and anti-infective portfolio, achieving significant quarter on quarter growth during his tenure with MSD.

Jason earned a Master of Business Administration from the University of Manchester and a Bachelor of Science (Pharmacy) from the National University of Singapore.

Jason will report to Mr. Paul Lim, Country Head for Singapore, and OTC Lead for Singapore, Philippines and Indonesia.

At Wellesta, we see opportunity for good growth within the Singapore Pharmaceutical & OTC industry with the addition of Jason to the Wellesta team. We welcome him to our Wellesta family and look forward to his dedicated contribution in the overall management and growth of Wellesta business in Singapore.

Mr. Dennis Lim has been appointed as Regulatory Specialist for Singapore with effect from 6 Sep 2021.

Prior to joining Wellesta Singapore, Dennis worked as a senior pharmacist in Changi General Hospital where he provided professional clinical pharmacy services to various departments. In particular, he started with specialties including Cardiology, Dermatology, Otorhinolaryngology, Gastroenterology, Ophthalmology, General Medicine, and Renal Medicine, before focusing on Geriatric Medicine, Neurology and Psychiatry. With several years of experience in a fast-paced restructured hospital, he is adept at implementing innovative practices and procedures to improve process efficiency, staff productivity and patient care experiences.

He is a registered Pharmacist with a Bachelor of Pharmacy degree from the National University of Singapore where he graduated with 1st Class Honors.

At Wellesta, we see opportunities for good growth within the Singapore Pharmaceutical & OTC industry with the addition of Dennis to the Wellesta team. We welcome him to our Wellesta family and look forward to his dedicated contribution in the overall management and growth of Wellesta business in Singapore.

Naari Pte Ltd & Wellesta Holdings Pte Ltd are pleased to announce its joint venture for Singapore as NaariEsta Pte Ltd. Naari will be investing 65% and Wellesta would invest 35% in the joint venture. This will be a vertically integrated, women’s health focused company: NaariEsta Pte Ltd, operating in Singapore and Brunei markets.

Naari Pte is headquartered in Singapore and has development and manufacturing capabilities for fermentation intermediates, active pharmaceutical ingredients and finished dosage forms. Apart from a vast portfolio of generic APIs and FDFs, Naari has other innovative products at various stages of development and clinical trials. Naari’s mission is to have a comprehensive product portfolio that serves the needs of women throughout their lives – from puberty, through pregnancies, menopause and post-menopause.

Wellesta is a company headquartered in Singapore and its main specialty is in Marketing, Brand Management, Sales & Operations with world-class standards in its business approach and compliance. Its focus is on the Asia Pacific market to provide pharmaceutical and medical devices and consumer healthcare products. Wellesta aims to be a valued partner to healthcare companies in serving the community in Singapore and the Asia Pacific with a cost-effective and wide range of pharmaceutical and healthcare products, with women-care being one of the focus areas. The joint-venture offers win-win synergies for both companies.

The joint venture between the two companies provides opportunities for synergy, with Naari bringing in products from both the prescription and the OTC line, as well as medical devices and other products. Wellesta’s comprehensive understanding of the market aims to provide the right platform for the products to expand towards to greater heights. The joint venture will be a union of the two companies offering a comprehensive women's health portfolio with an aim to provide products and be a partner in the journey of overall wellness of women in Singapore. With niche and diversified product portfolio, NaariEsta would have access to women's healthcare market in Singapore of about USD 20 million and will start realizing the revenues from April'2021 onwards.

Both Wellesta and Naari operate based on the principles of High Integrity, Value-added partner and Full Transparency for our principals. With this, NaariEsta’s mission to serve women’s needs by providing high-quality healthcare products and services at an optimum price will be achieved through this joint venture which will be driven by our commitment, in-market expertise and efficient enactment.

We are pleased to announce the collaboration of Wellesta and Cureleads.

Wellesta is a company headquartered in Singapore and support Healthcare companies to expand their reach of products for larger access to patients & brand building by way of offering sales, marketing & distribution. It also helps smaller MNC’s & Biotech companies as launch pad for their products to be launched in Asia Pacific. Wellesta is led by Industry Proven leaders at HQ & Country level.

Cureleads is a company headquartered in Dubai & Beirut and aspires to transform patient’s lives by leading the path to cure specialty and rare diseases. It is founded by highly profiled industry leaders regionally and globally.

Cureleads is involved in the business of distribution and marketing of medicinal and pharmaceutical products in Middle East, Dubai & North Africa.

Wellesta is in the business of marketing, brand creation, sales & distribution of medicinal and Healthcare products with focus on Asia Pacific.

With this collaboration both companies can help companies to get coverage across Asia Middle East & Africa (AMEA) geographies. Both companies operate on the principles of High Integrity, Value added partner & Full transparency for our Principals. This alliance will help companies get a partner which provides excellent reach in AMEA countries.

Apart from this, both companies will also provide bilateral support for each other through medical talks, health fairs, newsletters and websites or such other media. They will carry out joint research on the demographics, risk profiles and care needs of the population in both territories from time to time.

Thus, Wellesta’s goal to support and provide high quality healthcare products & services at optimum price to improve health access to masses, and Curelead’s goal to lead the transformation of patients’ lives & curing speciality diseases will be accomplished through this collaboration in Asia Middle East & Africa. Our focus would be driven through our dedicated efforts, strong in-market experience, best-in class capabilities, determination and excellent execution.

Mr. Paul Lim has been appointed as Country Head for Singapore and OTC Lead for Singapore, Malaysia and Indonesia with effect from 1st March, 2020.

Mr. Lim previously worked at Church & Dwight where he launched and achieved market leadership in numerous countries in the Nasal care and VMS categories as OTC Lead - Asia Pacific. Mr. Lim is a highly motivated and experienced commercial leader with over 18 years of experience in the pharmaceutical and consumer health industry across Asia Pacific.

With his expertise and robust experience, he has held various key commercial roles in multinational companies such as Pfizer, Alcon and Church & Dwight. He also enabled Alcon Singapore to extend its leadership in the pharmaceutical franchise of ophthalmology as Business Unit Head.

He holds Bachelor of Business degree from the University of Central Queensland and has completed his coursework for Global MBA from University of London.

We at Wellesta see good opportunity for Singapore Pharma & OTC Market and in other SE emerging markets. With addition of Mr. Lim to Wellesta team, would help driving opportunities and meet the Vision and Mission of our company.

Mr. Lim will report to Milan Paleja, Director of Wellesta Healthcare Singapore Pte Ltd & also Chairman & MD of Wellesta Group.

We welcome Mr. Paul Lim, who is now based in Singapore, to our Wellesta family. We look forward for his dedicated contribution in the overall management and growth of Wellesta business in Singapore as well as being the Lead for the OTC Businesses in Malaysia and Indonesia.